Avantium (AVTX) H1 2025 earnings summary

Executive summary

• Leading developer of FDCA/PEF, pioneering bio-based plastics with a flagship plant in the Netherlands expected to start commercial production in Q1 2026, though start-up was delayed to January 2026.

• Strong commercial momentum with 20 offtake agreements, 7 capacity reservations, and 1 license agreement signed.

• Comprehensive financing package secured, including €65m in equity and €15m from the Dutch Ministry of KGG, with a fully underwritten €65m equity raise planned for September 2025.

• Major cost savings and restructuring initiatives launched, including a planned reduction of 40 FTEs and renegotiation of supplier contracts.

• Ambition to reach €90m in revenues and EBITDA break-even by 2027, including R&D Solutions.

Financial highlights

• 1H 2025 revenues reported as €6.7m, down 25% year-over-year, with Renewable Polymers revenue falling by €2.9m.

• EBITDA loss increased to €(18.5)m from €(16.3)m year-over-year; net loss narrowed to €11.1m from €14.8m.

• Investments/CAPEX decreased to €6.0m from €26.0m in 1H 2024.

• Cash position at 1H 2025 was €12.0m, including €3.5m restricted cash, down from €23.9m at FY 2024.

• Borrowings reported as €120.6m outstanding, with average effective interest rate of 27%.

Outlook and guidance

• Commercial scale FDCA production to begin in Q1 2026, with first product sales anticipated then.

• Targeting four licensing agreements by end of 2027; active discussions ongoing with 10 potential licensees.

• Path to profitable growth with EBITDA break-even and €90m revenue ambition in 2027.

• Success of the equity raise and cost savings program are critical to ongoing operations and liquidity.